Breaking Cataract Patient Education Surgery Technology Alcon presenting at APACRS 2025 Ağustos 21, 2025
Breaking Clinical Trial Myopia Treatment OCT changes with low-level red light therapy for myopia in children Ağustos 26, 2025
Breaking Cornea Innovation Patient Education Treatment Surgical innovation in dry eye disease: Salivary gland transplant Ağustos 27, 2025
Breaking Cataract Patient Education Recommendation Surgery Treatment Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery Eylül 10, 2025
Home Industry News ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones – Laotian Times Share your love
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones Laotian Times Source: Author: | Date: 2025-09-02 12:00:00 Source: Author: | Date: 2025-09-02 12:00:00 Share your love Previous Yazı EyeCool Therapeutics names Dr Vance Thompson to Board - Medical Buyer Next Yazı ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones - The Globe and Mail Related Posts FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025 AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025 Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology TimesEkim 3, 2025 Leave a ReplyCancel ReplyE-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Yorum gönder
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025
